## Maria Elena Ainora

## List of Publications by Citations

Source: https://exaly.com/author-pdf/405377/maria-elena-ainora-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16<br/>papers760<br/>citations10<br/>h-index17<br/>g-index17<br/>ext. papers936<br/>ext. citations3.2<br/>avg, IF3<br/>L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 16 | Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 682-9            | 13.4 | 321       |
| 15 | Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 485-492        | 13.4 | 116       |
| 14 | Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 323-7            | 0.7  | 79        |
| 13 | Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1014-21 | 13.4 | 57        |
| 12 | Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. <i>Gastroenterology Research and Practice</i> , <b>2012</b> , 2012, 740381           | 2    | 52        |
| 11 | Rifaximin pharmacology and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2009</b> , 5, 675-82  | 5.5  | 35        |
| 10 | Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 4437-4451                                     | 5.6  | 28        |
| 9  | Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1866-74                    | 3.4  | 20        |
| 8  | Diagnosis of bowel diseases: the role of imaging and ultrasonography. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 2144-53   | 5.6  | 17        |
| 7  | Usefulness of contrast-enhanced ultrasound (CEUS) in Inflammatory Bowel Disease (IBD). <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 761-767  | 3.3  | 13        |
| 6  | Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience. <i>Journal of Ultrasound</i> , <b>2019</b> , 22, 157-165   | 3.4  | 8         |
| 5  | Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. <i>Digestive Diseases</i> , <b>2020</b> , 38, 522-533                                | 3.2  | 5         |
| 4  | Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma <i>Cancers</i> , <b>2022</b> , 14,  | 6.6  | 5         |
| 3  | Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. <i>Scientific Reports</i> , <b>2019</b> , 9, 15373                    | 4.9  | 3         |
| 2  | A new ultrasound score for the assessment and follow-up of chronic pancreatitis: The <b>G</b> emelli USCP scorea <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 644-650                          | 3.3  | 1         |
| 1  | Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohnæ disease patients undergoing anti-TNFItherapy. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 729-737            | 3.3  | 0         |